Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

Highly Accessed Editorial

IL-17 in spondyloarthritis: is the T-party over?

Nataliya Yeremenko and Dominique Baeten*

Author Affiliations

Clinical Immunology and Rheumatology, G4-212, Academic Medical Center/University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands

For all author emails, please log on.

Arthritis Research & Therapy 2011, 13:115  doi:10.1186/ar3351

Published: 24 June 2011

Abstract

The past decade has witnessed significant progress in revealing an important role for IL-17 in the pathogenesis of several immune-mediated inflammatory diseases. Recent studies have provided new insights into the cellular source of IL-17, originally identified as the signature cytokine of a distinct CD4+ T-cell subset known as Th17. Accumulating evidence suggests that the majority of the IL-17 released in inflammatory arthritis is produced by innate immune cells rather than T cells. Understanding molecular mechanisms behind these early innate immune responses will be the key to designing rational therapies targeting these important inflammatory pathways.